Report error Found 101 Enz. Inhib. hit(s) with all data for entry = 11186
Affinity DataIC50: 0.200nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 5.70nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 6.10nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 7.20nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 11.4nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 17.5nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 18.5nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
3D Structure (crystal)
Affinity DataIC50: 30.1nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 31nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 38.2nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 39.3nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 39.7nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 42.5nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 43nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 58nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 61.3nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 63nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 67.6nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 71nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 72nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 73.1nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 89.5nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 90.1nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 97.6nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 99.5nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 100nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 111nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 115nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 119nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 130nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 134nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 150nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 156nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 161nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 164nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 185nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 190nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 198nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 203nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 208nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 223nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
Affinity DataIC50: 250nMAssay Description:In one embodiment, the present invention provides compounds of formula (Ie) and their pharmaceutically acceptable salts as described herein, wherein ...More data for this Ligand-Target Pair
